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The structure of mouse L 1210 dihydrofolate r ductase (DHFR) complexed with NADPH and trimethoprim 
has been refined at 2.0/~ resolution. The analogous complex with NADPH and methotrexate has been re- 
fined at 2.5 A resolution. These structures reveal for the first time details of drug interactions with a mamma- 
lian DHFR, which are compared with those observed from previous X-ray investigations ofDHFR/inhibi- 
tor complexes. The refined L1210 structure has been used as the basis for the construction of a model of 
the human enzyme. There are only twenty-one sequence differences between mouse L1210 and human 
DHFRs, and all but two of these are located close to the molecular surface: a strong indication that the 
active sites are essentially identical in these two mammalian enzymes. 
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1. INTRODUCTION 
Dihydrofolate reductase (DHFR) catalyses the 
NADPH-dependent reduction of dihydrofolate to 
tetrahydrofolate hereby maintaining the pool of 
tetrahydrofolate-derived coenzymes that are uti- 
lised in various one-carbon transfer eactions [1]. 
A number of clinically important drugs act 
through inhibition of DHFR. Thus the an- 
tibacterial, trimethoprim (TMP) inhibits bacterial 
DHFR selectively, showing about 3000-fold less 
affinity for mammalian DHFRs [2]. Methotrexate 
(MTX) shows high affinity for a wide range of 
DHFRs from different species, including mam- 
malian enzyme [3], and is used as an anti-cancer 
agent. 
Correspondence address: D.K. Stammers, Wellcome 
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The three-dimensional structures of DHFRs 
from several sources have been extensively studied 
[4-11]. In order to understand better the structural 
basis of drug selectivity and to apply this 
knowledge to the design of novel inhibitors, an X- 
ray study of DHFR from mouse L1210 tumour 
cells was undertaken. This enzyme shows con- 
siderably higher sequence homology with human 
DHFR [12] than any other DHFR structure 
reported. A preliminary report of the L1210 
DHFR/NADPH/TMP structure at 2.5 A resolu- 
tion has already been given [13]. The data have 
now been extended to 2.0 A and the structure 
refined. The MTX ternary complex has been re- 
fined at 2.5 A. These studies have provided detail- 
ed information on drug-enzyme interactions in the 
mammalian system. Further, a model of human 
DHFR has been built, based on the refined L1210 
structure and the human sequence. 
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2. MATERIALS AND METHODS 
DHFR prepared from L1210 cells [13] was 
dialysed against TMP and NADPH (1 mM) in 
50mM Hepes (Na+), pH 7.8; the enzyme 
(20 mg/ml) was then crystallised by vapour diffu- 
sion, polyethylene glycol 6000 being used as the 
precipitant (8-24%, w/v). The space group of the 
crystals was P2~ with unit cell dimensions a = 
43.7 ,~, b = 61.6 ,~, c = 41.9 ,/~ and ~ = 116.3 °, 
with a single molecule per asymmetric unit. Data 
were collected to 2.0 A resolution from a single 
crystal by means of an automatic oscillation 
camera [14]. Crystals of the DHFR/NADPH/  
MTX complex, which diffracted to 2.5 ,~ resolu- 
tion, were prepared by soaking pre-grown crystals 
in 1 mM MTX, to displace TMP. 
The model derived from the earlier 2.5/~, resolu- 
tion map [13], phased with two isomorphous heavy 
atom derivatives, was used as the starting-point for 
refinement by the restrained least-squares method 
of Hendrickson and Konnert [15]. The current 
model is a result of three rounds of reconstruction, 
by means of a VAX version of the modelling pro- 
gram FRODO [16], together with least-squares 
refinement iterated to convergence after each 
round of rebuilding. An Evans and Sutherland 
PS300 display system fitted with a Leeds Universi- 
ty liquid crystal stereo-viewer was used for the 
modelling process. The DHFR/NADPH/TMP 
model has an R value of 0.18 for data from 10 
to 2.0 A resolution, and the mean uncertainty in 
atomic position is 0.1 ,/k. All 1519 non-hydrogen 
protein atoms are contained in the model, together 
with 48 NADPH atoms, 21 TMP atoms and 290 
water molecules. This model was used as the start- 
ing point for refinement of the MTX ternary com- 
plex. Three rounds of building and refinement, as 
for TMP, incorporating data from 10 .~ to 2.5 ,~, 
resulted in a final R value of 0.19. 
3. RESULTS AND DISCUSSION 
3.1. Trimethoprim binding 
The binding of TMP to mouse L1210 enzyme, 
depicted in fig.l, is essentially similar to that 
reported [7,17] for a range of substituted ben- 
zylpyrimidines, including TMP, in complex with 
chicken liver enzyme. Specific points to be dis- 
cussed for L1210 DHFR concern the conformation 
of Phe-31 and the interactions of TMP with the ad- 
jacent active site residues. 
The Phe-31 side-chain has torsion angles of 
-165 ° for N-Cxr-C~oC7 and 78 ° for C~-C~-C7- 
CA. This conformation places its aromatic moiety 
in van der Waals contact with side-chains Phe-34 
and Gin-35, and with the p-methoxy group of 
TMP. The ligand itself is located in the enzyme ac- 
tive site such that the N1 and 2-amino groups of 
the diaminopyrimidine form hydrogen bonds to 
Glu-30, the 2-amino group makes a hydrogen bond 
with Thr-136 via a water molecule, and the 
4-amino group hydrogen bonds to the carbonyl of 
Ile-7. The carbonyl oxygen of Val-115 is too dis- 
tant from the 4-amino group for a hydrogen bond 
to be made. The latter feature is similar to the case 
of chicken enzyme and contrasts with that of E. 
coli enzyme [7,8]. Ile-7 and Val-115 carbonyl ox- 
ygens of mouse DHFR are in fact about 0.6 ,~, fur- 
ther apart than those of the equivalent E. coli 
DHFR residues. Such a separation in mouse 
DHFR allows the hydroxyl group of Tyr-121 to lie 
quite close to the 4-amino nitrogen and to the car- 
bonyl oxygen of Ile-7, and to hydrogen bond with 
the latter. The diaminopyrimidine group makes 
van tier Waals interactions with the side-chains of 
Ile-7, Ala-9 and Phe-34, with the main-chain of 
Val-8, with the Tyr-121 hydroxyl group and with 
the carbonyl oxygen of the nicotinamide moiety of 
NADPH. TMP has torsion angles of -96  ° 
(C4-C5-C7-C1') and 85 ° (C5-C7-C1'-C2') with 
the valence angle at the methylene opened out to 
119 °, a larger value than is observed for any of the 
five TMP structures in the Cambridge Crystallo- 
graphic Data-Base, whose average value is 115.1 °. 
The TMP conformation is close to one of three 
possible solutions proposed from NMR studies of 
the L1210 DHFR/TMP complex [11]. As a con- 
sequence of the TMP geometry, van der Waals in- 
teractions occur between the trimethoxybenzene 
group and the side-chains of Leu-22, Phe-31, 
Phe-34, Ile-60 and Val-115. 
The TMP binding described above has features 
akin to the interaction between the isopropenyl 
isostere of TMP and chicken DHFR [17]. In the in- 
teraction of TMP with chicken DHFR [7], by com- 
parison with mouse DHFR, the C5-C7-C1'-C2' 
torsion angle of TMP is about 20 ° greater. Fur- 
thermore, the two Tyr-31 torsion angles (about 
-75  ° and 180 ° ) completely relocate the side- 
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Fig. 1. Stereo-view of trimethoprim complexed with mouse L 1210 DHFR and NADPH. The skeletal molecular structure 
of the ligands and the enzyme active site are shown superimposed on an a-carbon enzyme backbone. 
chain, relative to the position of the corresponding 
Phe-31 side-chain in the mouse DHFR, so that its 
hydroxyl group hydrogen bonds via a water 
molecule to the carbonyl oxygen of Trp-24. The 
energy difference for these two Tyr-31 conforma- 
tions is probably small [17]. The relocation is 
readily accommodated given the slight change in 
ligand folding. The opened-out methylene valence 
angle of TMP in the mouse DHFR complex ap- 
pears to be necessary to optimise the additional 
van der Waals contact of the drug with the side- 
chain of Phe-31. 
From a comparison of interatomic distances 
around the active sites of both chicken and E. coli 
enzymes, Matthes et al. [17] showed that the 
vertebrate active site is significantly larger than the 
bacterial, and deduced that TMP binding in 
vertebrate nzyme in a conformation similar to 
that found in E. coli enzyme would not be 
energetically favourable. A similar comparison 
(table 1) between L1210 and E. coli enzymes of cer- 
tain active site interatomic distances indicates once 
again a larger active site for the vertebrate enzyme 
than for the bacterial enzyme, though further in- 
spection of these data by reference to table III of 
Matthews et al. [17] suggests that of the two 
vertebrate sites, the mouse active site is somewhat 
smaller. A significant difference in secondary 
structure between bacterial and vertebrate enzyme 
is also demonstrated by table 1. The difference 
distances involving residue 31 are all smaller, most 
by several tenths of an Angstrom, than the cor- 
responding differences involving the adjacent 
residue 30. In fact there is a distortion of the helix 
in this region of the vertebrate structure that is not 
present in E. coli enzyme. 
3.2. Methotrexate binding 
The binding of the pteridine moiety of MTX (see 
fig.2) is similar to that observed in bacterial 
DHFRs, despite some differences in the overall 
shape and size of the active site. Thus there are 
hydrogen-bond interactions between N1 and the 
carboxylate group of Glu-30, analogous to Asp-27 
in E. coli enzyme (ec), between the 2-amino group 
and Glu-30, between the 2-amino group and 
Thr-136 via a water molecule (cf. Thr-113ec), and 
between the 4-amino group and the backbone car- 
bonyl oxygens of Ile-7 and Val-115 (cf. Ile-7ec and 
Ile-94ec). This last interaction with mouse DHFR 
is not observed for TMP, as indicated earlier, 
which undoubtedly contributes to the relatively 
weak interaction of that drug with mammalian 
DHFR. A conserved water molecule forms a 
hydrogen-bond bridge from the carboxylate group 
of Glu-30 to the side-chain of Trp-24 (cf. 
Trp-22ec). 
There are a number of non-polar interactions 
180 
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Table 1 
Table of difference distances for certain DHFR active-site atoms 
Ca-7 Ca-30 Ca-31 Ca-34 Ca-60 Ca-67 Ca-115 
Ca-136 -0.13 + 1.10 +0.05 -0.16 + 1.15 +0.17 +0.27 
Ca-115 +0.11 + 1.35 +0.18 +0.16 +0.67 -0.34 
Ccr-67 -0.50 +0.79 +0.50 +0.17 +0.77 
Ca-60 +0.62 + 1.56 + 1.02 +0.85 
Ca-34 - 0.34 + 0.43 - 0.26 
Ca-31 -0.38 0.00 
Ca-30 +0.89 
The differences are D(m) - D(c), where D is the distance (A) between apair of 
a-carbons in either mouse L1210 DHFR (m) or E. coli DHFR (c). The numbers 
denote Ca positions based on the sequence for mouse enzyme 
between the pteridine ring and mouse DHFR, in- 
volving the side-chains of Ile-7, Ala-9, Leu-22, 
Phe-31 and Phe-34, and backbone atoms of Val-8 
and Ala-9. The main differences observed from 
bacterial DHFRs concern the relative positions of 
the side-chains of Leu-28ec and Phe-31ec (Leu-27 
and Phe-30 in Lactobacillus casei enzyme) which 
are approximately perpendicular to each other, 
whereas the corresponding side-chains in mouse 
DHFR (Phe-31 and Phe-34) are approximately 
parallel. 
The p-aminobenzoyl group of MTX is surround- 
ed by hydrophobic groups. On one side, the ring is 
in contact with the side-chains of Phe-31 and 
Phe-34. Apparently as a consequence of the dif- 
ferent orientation of Phe-31 relative to the 
counterpart E. coli Lue-28ec side-chain, the ben- 
zoyl group is rotated by approx. 60 ° compared to 
its orientation in the bacterial enzyme. This in turn 
alters the contacts made by the opposite face of the 
ring. Thus the van der Waals interaction with 
Leu-54ec of E. coli enzyme is not observed for 
mouse enzyme. A further interaction in E. coli en- 
zyme, between Arg-52ec and the benzoyl oxygen of 
MTX, is not observed for mouse DHFR owing to 
a three-residue insertion of Glu-Lys-Asn (residues 
62-64) which alters the position of the analogous 
Arg-65. (A single insertion in L. casei enzyme at 
I I  
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Fig.2. Methotrexate complexed with mouse L1210 DHFR and NADPH. The view is similar to that shown in fig.l. 
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residue 51 likewise causes an alteration to the 
backbone conformation so that this same interac- 
tion is lost.) 
The binding of the glutamyl moiety of MTX is 
less clearly defined in the structure than are the 
pteridine or p-aminobenzoyl parts. The most con- 
vincing interpretation has the 7-carboxylate group 
making no hydrogen-bond interaction with the 
protein whilst the a,-carboxylate group hydrogen 
bonds via a water molecule to the side-chain of 
Gln-35; no interaction of the a,-carboxylate with 
Arg-70 (cf. Arg-57ec) is observed. This is 
somewhat surprising, given that a-substitution of 
MTX increases the Ki by about 105 [18], consistent 
with an ionic interaction of the a,-carboxylate with, 
for example, Arg-70. As the MTX complex was 
prepared by the soaking of pre-grown 
DHFR/NADPH/TMP crystals in the inhibitor, it 
is possible that packing constraints within the 
crystal are preventing either earrangement of pro- 
tein side-chains (improbably, given the presence of 
a large solvent-filled cavity in this region) or a 
more substantial conformational change. 
3.3. Human dihydrofolate reductase 
The high sequence homology of 89°70 between 
mouse L1210 DHFR [19] and human DHFR 
[20,21] strongly suggests a close similarity between 
the two structures; this is confirmed by the model- 
ling of the twenty-one sequence differences of 
human enzyme into the L1210 structure. Fig.3 in- 
dicates the locations of the side-chains ubstituted 
in human enzyme. 
The model shows that of the twenty-one amino 
acid differences (table 2) from mouse L1210 
DHFR, nineteen occur in solvent-accessible 
regions on or near the surface of the molecule. 
Fourteen involve the exchange of one polar residue 
for another, three replace non-polar residues in 
mouse DHFR by polar residues in human DHFR, 
and two replace polar residues in mouse DHFR by 
glycine in human DHFR. Fourteen of the dif- 
ferences are in loop regions between elements of 
secondary structure. There are none at the 
substrate binding site and only one at the NADPH 
binding site. As can be seen from table 2, many of 
the side-chains in L1210 DHFR that are different 
in human DHFR do not interact with other atoms 
of the protein but project into the solvent region. 
The human DHFR side-chain substitutions have 
similarly been modelled to have an extended con- 
formation. In some cases ordered solvent exists 
around DHFR which has to be modified in the 
human enzyme, owing to differing side-chain 
length or hydrogen-bonding capability. An exam- 
ple is Glu-127 which changes to His-127 in human 
ql l [ |  ! 
Fig.3. Stereo-view of mouse DHFR molecule, showing the 21 side chains that are replaced in human DHFR. 
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Table 2 
Human DHFR: sequence changes from mouse LI210 DHFR 
Location • Mouse Human Position a Main side-chain contacts in 
Mouse Human 
2 Arg Gly s 
3 Pro Ser s 
32 Lys Arg s 
54 Arg Lys s 
69 Asp Gly s 
73 Ile Leu i 
84 Arg Gin s 
90 Ala Ser p 
solvent 
solvent Lys-132 or solvent 
solvent solvent 
2' -phosphate 2' -phosphate 
of NADPH of NADPH 
solvent 
Ile-100 Thr-100 
solvent solvent 
4A from main- H.bond to >C= O 
chain 95/96 of 92 
91 Lys Arg s solvent solvent 
98 Arg Lys s solvent solvent 
100 Ile Thr i Ile-73 Leu-73 & H.bond 
to>C=Oof96  
107 Ser Asn p solvent Nt~ H.bond to 
>C=Oof  104& 
of 105 
122 Glu Lys s solvent solvent 
123 Gin Glu s solvent solvent 
127 Glu His s solvent solvent; displaces 
one water 
132 Arg Lys s solvent solvent, or OH 
of Ser-3 
141 Glu Asp s solvent solvent 
154 Gly Glu s - solvent 
168 Glu Asp s solvent solvent 
173 Asp Lys s solvent solvent 
185 Lys Asn s solvent solvent 
a s, surface residue; p, partly buried residue; i, internal residue 
DHFR, the NE2 atom of which displaces one of the 
L1210 water molecules and could hydrogen bond 
via another water to Glu-123. 
Two differences, 90 and 107, are at partly buried 
sites. Ala-90 is replaced by Ser-90 whose hydroxyl 
group can donate a hydrogen bond to the 
backbone carbonyl group of residue 92. Whilst 
Ser-107 makes no hydrogen bond in mouse L1210 
DHFR,  Asn-107 in human DHFR can make 
hydrogen bonds between its N~ and the backbone 
carbonyls of 104 and 105 and between its Ot~ and 
a nearby water. 
Ile-73 to Leu and Ile-100 to Thr are the only two 
sequence differences in regions inaccessible to sol- 
vent. They lie adjacent o each other in mouse 
DHFR in a hydrophobic environment. Replace- 
ment of Ile-100 by the smaller Thr-100 in human 
DHFR gives rise to a decrease in packing density 
and a number of orientations for Leu-73 and 
Thr-100 are then possible. The effect of the polar 
residue in this hydrophobic environment can be 
reduced by allowing the hydroxyl group of Thr-100 
to donate a hydrogen bond to the backbone car- 
bonyl of residue 96. 
The single difference at a ligand binding site is 
the conservative substitution of Lys-54 in human 
DHFR for Arg-54. The E-amino group of Lys-54 
can interact with the 2' -phosphate of NADPH in 
place of the guanidinium group of Arg-54. 
4. CONCLUSIONS 
The refined structures reported above give 
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details of how certain antifolate drugs interact with 
a mammalian DHFR. The observed ifferences in 
TMP and enzyme conformation between mouse 
L1210 DHFR and chicken DHFR relate primarily 
to the substitution of Phe-31 for Tyr-31. Com- 
parison with E. coli DHFR reveals that TMP 
bound to L1210 DHFR is in a significantly dif- 
ferent conformation, and that fewer interactions 
between the diaminopyrimidine moiety and the 
protein are present, consistent with the drug's 
lower affinity for L1210 enzyme. In contrast, with 
MTX, equivalent interactions occur between the 
pteridine group and either enzyme. The distinct 
Phe-3i conformation in the mouse DHFR/MTX 
ternary complex requires an orientation of the p- 
aminobenzoyl glutamate moiety altered from that 
observed in bacterial DHFR/MTX complexes. 
Further studies are required to assess the 
significance of this observation. 
The human DHFR model, derived by fitting the 
human amino acid sequence to the mouse L1210 
DHFR structure, shows no steric hindrances, and 
the changes in electrostatic nteractions are minor 
and remote from the substrate binding site. 
Although possible small changes in vibrational 
modes which might affect catalytic activity cannot 
be discounted, we conclude that the structure of 
the mouse L1210 enzyme around the substrate 
binding site represents a good model of human 
DHFR for use in drug design. 
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